CGX 1007

Drug Profile

CGX 1007

Alternative Names: Con-G; Conantokin G

Latest Information Update: 14 Jan 2008

Price : $50

At a glance

  • Originator Salk Institute; University of Utah
  • Developer Cognetix
  • Class Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Epilepsy; Neurodegenerative disorders; Pain

Most Recent Events

  • 26 Oct 2005 Discontinued - Phase-I for Neurodegenerative disorders in USA (IV)
  • 26 Oct 2004 CGX 1007 is available for licensing (http://www.cognetix.com)
  • 26 Oct 2004 Discontinued - Phase-I for Epilepsy in USA (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top